(Q44682383)

English

Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Ejlertsen B

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Højris I

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Hansen S

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Møholt K

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Kristensen B

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Mouridsen HT

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Andersen J

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Rose C

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Kjaer M

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

publication date

1 February 2003

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

42-50

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of chemotherapy on survival after recurrence in breast cancer--a population-based study of patients treated in the 1950s, 1960s and 1970s

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Myocardial ischemia and infarction associated with vinorelbine.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2802%2900180-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0960-9776(02)00180-7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44682383&oldid=2031650204"